OCULAR THERAPEUTIX, INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $52.0M | $63.7M | $58.4M | $51.5M | $43.5M |
| Cost of revenue | $6.6M | $5.6M | $5.3M | $4.5M | $4.4M |
| Research and development | $197.1M | $127.6M | $61.1M | $53.5M | $50.1M |
| Operating income | -$270.0M | -$171.8M | -$82.4M | -$78.7M | -$78.0M |
| Interest expense | $11.8M | $13.6M | $11.3M | $7.0M | $6.7M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$265.9M | -$193.5M | -$80.7M | -$71.0M | -$6.6M |
| Balance Sheet | |||||
| Cash and equivalents | $737.1M | $392.1M | $195.8M | $102.3M | $164.2M |
| Current assets | $782.1M | $441.0M | $232.2M | $129.6M | $191.3M |
| Total assets | $808.1M | $457.9M | $252.1M | $149.3M | $204.9M |
| Current liabilities | $50.8M | $41.4M | $34.9M | $31.4M | $26.3M |
| Total liabilities | $153.7M | $142.6M | $160.9M | $113.9M | $116.9M |
| Stockholders' equity | $654.3M | $315.3M | $91.1M | $35.4M | $88.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$204.9M | -$134.7M | -$70.2M | -$59.6M | -$65.5M |
| Depreciation and amortization | $4.3M | $3.8M | $3.0M | $2.1M | $2.4M |
| Stock-based compensation | $43.2M | $33.1M | $17.8M | $17.0M | $15.0M |
| Capital expenditure | $12.0M | $1.3M | $6.1M | $3.7M | $1.2M |
| Free cash flow | -$216.9M | -$136.0M | -$76.3M | -$63.3M | -$66.7M |
Shares outstanding 219.0M · Free float 90.2%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.